Epigenetic regulation of mmp-9 gene expression

被引:0
作者
Marilyne Labrie
Yves St-Pierre
机构
[1] INRS-Institut Armand-Frappier,
来源
Cellular and Molecular Life Sciences | 2013年 / 70卷
关键词
MMP-9; Epigenetics; DNA methylation; Non-coding RNA; Histone; Cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Matrix metalloproteinase 9 (MMP-9) is one of the most studied enzymes in cancer. MMP-9 can cleave proteins of the extracellular matrix and a large number of receptors and growth factors. Accordingly, its expression must be tightly regulated to avoid excessive enzymatic activity, which is associated with disease progression. Although we know that epigenetic mechanisms play a central role in controlling mmp-9 gene expression, predicting how epigenetic drugs could be used to suppress mmp-9 gene expression is not trivial because epigenetic drugs also regulate the expression of key proteins that can tip the balance towards activation or suppression of MMP-9. Here, we review how our understanding of the biology and expression of MMP-9 could be exploited to augment clinical benefits, most notably in terms of the prevention and management of degenerative diseases and cancer.
引用
收藏
页码:3109 / 3124
页数:15
相关论文
共 939 条
[61]  
Degerny C(2009)The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression Int J Oncol 34 573-6224
[62]  
Verreman K(2011)The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine Int J Oncol 38 1421-2457
[63]  
Cowden Dahl KD(2010)MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis Neuroscience 169 370-4004
[64]  
Zeineldin R(2006)HER-2/neu represses the metastasis suppressor RECK via ERK and Sp transcription factors to promote cell invasion J Biol Chem 281 4718-5407
[65]  
Hudson LG(2001)HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1 Oncogene 20 6215-1421
[66]  
Qin L(2001)Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer Clin Cancer Res 7 2448-1370
[67]  
Liao L(2001)HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression Mol Cell Biol 21 3995-359
[68]  
Redmond A(2002)Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer Cancer Res 62 5405-1356
[69]  
Young L(2004)Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera Br J Cancer 90 1414-5622
[70]  
Yuan Y(2010)Inhibition of histone deacetylase attenuates hypoxia-induced migration and invasion of cancer cells via the restoration of RECK expression Mol Cancer Ther 9 1361-1460